Cryoport Q2 revenue $57M (-11% YoY), net loss $18.4M; FY guidance $233-243M

Cryoport, Inc.

2023-Q2 EPS reported -$0.58 revenue$119,838,000

Revenue $57.0M, down 11% YoY; net loss attributable to common $20.4M ($0.42/share) vs. $11.2M loss a year ago.
MVE China revenue fell 67% YoY ($5.8M decline); slower client ramps also hit Biopharma/Pharma segment.
Bioservices revenue rose 38% to $3.2M; commercial therapy revenue up 9.2% to $4.3M.
Adjusted EBITDA was -$1.5M, down $7.5M YoY from $6.0M; net loss widened to $18.4M from $9.2M.
FY2023 revenue guidance $233-243M; cash & short-term investments $504.7M at June 30.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cryoport, Inc. reported the second quarter ended June 30, 2023 results: revenue $57.0 million.

Period: the second quarter ended June 30, 2023
Revenue: $57.0 million
Result: reported results

Exact text from the filing

--- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 tm2323346d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports Second Quarter 2023 Financial Results § Second quarter revenue of $57 million, in line with previously announced preliminary results § Clinical trials supported by Cryoport increased to a record 668 global clinical trials by quarter end; a net increase of

View on SEC.gov

Browse all earnings releases →

Cryoport, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-089376

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.